This variant, the let-7 complementary site (LCS6) in the KRAS 3′-UTR, is associated with KRAS gene upregulation and let-7 lower levels; however this polymorphism correlates with a modest increase in lung cancer risk [104]. Here, KRAS is linked to lung cancer.